Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Despite proven benefits, prophylactic treatment for hemophilia A is hampered by the short half-life of factor VIII. A recombinant factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an ∼ 2-fold longer half-life than rFVIII...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Dumont, Jennifer A., Liu, Tongyao, Low, Susan C., Zhang, Xin, Kamphaus, George, Sakorafas, Paul, Fraley, Cara, Drager, Douglas, Reidy, Thomas, McCue, Justin, Franck, Helen W. G., Merricks, Elizabeth P., Nichols, Timothy C., Bitonti, Alan J., Pierce, Glenn F., Jiang, Haiyan
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2012
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3953019/
https://ncbi.nlm.nih.gov/pubmed/22246033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-367813
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires